How #DDAmanda Stock Screener made 267% on $KTTA. This was a 200Day Low Bottom Play, which are detected by the scanner. Also Found Early by #DDAmanda: $TSLA, $NVDA, $PLTR, $AMD, $RGTI, $CIFR, $APLD, $SOFI, $RCAT #Best Early Alert Stock Screener: https://DDAmanda.com #DDamanda finds these befor

Pasithea Therapeutics (KTTA) will participate in two investor conferences in September 2026 to engage with investors and present its business.Management will hold one-on-one meetings at the 12th Annual Cantor Global Healthcare Conference in New York, NY, from September 9-11, 2026. Management will also present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, with the company’s presentation scheduled for Monday, September 14, 2026, at 2:30 PM ET. Pasithea is a clinical-stage biotech developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for chronic diseases including neurocutaneous manifestations of NF1.

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16), FiscalAI reports. Pasithea Therapeutics Stock Up 0.5% Shares of NASDAQ KTTA traded up $0.00 during mid-day trading on Friday, hitting $0.48. 43,254 shares of [...]

How #DDAmanda Stock Screener made 267% on $KTTA. This was a 200Day Low Bottom Play, which are detected by the scanner. Also Found Early by #DDAmanda: $TSLA, $NVDA, $PLTR, $AMD, $RGTI, $CIFR, $APLD, $SOFI, $RCAT #Best Early Alert Stock Screener: https://DDAmanda.com #DDamanda finds these befor

Full abstract will be published on ESMO website per Congress’

YouTube video by Stratolaunch

How #DDAmanda Stock Screener made 267% on $KTTA. This was a 200Day Low Bottom Play, which are detected by the scanner. Also Found Early by #DDAmanda: $TSLA, $NVDA, $PLTR, $AMD, $RGTI, $CIFR, $APLD, $SOFI, $RCAT #Best Early Alert Stock Screener: https://DDAmanda.com #DDamanda finds these befor

Pasithea management will take one-on-one investor meetings July 16 at B. Riley’s Boston summit, which covers neuropsychiatry, vision and neuromuscular disease.

Pasithea Therapeutics (NASDAQ:KTTA) amended the clinical protocol for its Phase 1/1b PAS-004 trial in NF1 patients with symptomatic inoperable, incompletely resected or recurrent plexiform neurofibroma.Changes add higher dose levels (24mg, 32mg), allow longer treatment up to 18 months, expand imaging and CN measurements, and support a planned interim NF1 data update in Q4 2026.

Pasithea Therapeutics (NASDAQ:KTTA) will exhibit at the Children's Tumor Foundation 2026 NF Conference, held June 26-30, 2026 in Denver, Colorado.The company plans to engage with the NF1 clinical and academic community following recent FDA Fast Track and Rare Pediatric Disease designations for its lead NF1 candidate PAS-004.

Pasithea Therapeutics (NASDAQ: KTTA) announced that the FDA has granted Orphan Drug Designation to PAS-004, a next-generation macrocyclic MEK inhibitor, for treating Amyotrophic Lateral Sclerosis (ALS).The designation offers potential tax credits, certain FDA fee exemptions, and up to seven years of market exclusivity after approval. Pasithea previously received a $1 million ALS Association grant in November 2025 to study PAS-004 in ALS.

How #DDAmanda Stock Screener made 267% on $KTTA. This was a 200Day Low Bottom Play, which are detected by the scanner. Also Found Early by #DDAmanda: $TSLA, $NVDA, $PLTR, $AMD, $RGTI, $CIFR, $APLD, $SOFI, $RCAT #Best Early Alert Stock Screener: https://DDAmanda.com #DDamanda finds these befor

News update via NF Bot